199 related articles for article (PubMed ID: 28972039)
1. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
Zauderer MG; Tsao AS; Dao T; Panageas K; Lai WV; Rimner A; Rusch VW; Adusumilli PS; Ginsberg MS; Gomez D; Rice D; Mehran R; Scheinberg DA; Krug LM
Clin Cancer Res; 2017 Dec; 23(24):7483-7489. PubMed ID: 28972039
[No Abstract] [Full Text] [Related]
2. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
Grosso F; Steele N; Novello S; Nowak AK; Popat S; Greillier L; John T; Leighl NB; Reck M; Taylor P; Planchard D; Sørensen JB; Socinski MA; von Wangenheim U; Loembé AB; Barrueco J; Morsli N; Scagliotti G
J Clin Oncol; 2017 Nov; 35(31):3591-3600. PubMed ID: 28892431
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
Kucukoner M; Ali Kaplan M; Inal A; Urakci Z; Abakay O; Cetin Tanrikulu A; Abakay A; Selim Sen H; Turkcu G; Senyigit A; Buyukbayram H; Isikdogan A
J BUON; 2014; 19(1):164-70. PubMed ID: 24659659
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
8. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
11. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
Sharkey AJ; O'Byrne KJ; Nakas A; Tenconi S; Fennell DA; Waller DA
Lung Cancer; 2016 Oct; 100():5-13. PubMed ID: 27597274
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
[TBL] [Abstract][Full Text] [Related]
13. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
14. Clinical Response of Live-Attenuated,
Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
[TBL] [Abstract][Full Text] [Related]
15. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
18. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
19. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
